Regulatory Johnson & Johnson’s multiple myeloma treatment secures EC approval Pharmaceutical Business ReviewThis decision provides a new therapeutic option for patients who have received at least one previous treatment.OncologyRead full story pharminent August 24, 2026 (Last updated: September 1, 2026) Pharmaceutical Business Review This decision provides a new therapeutic option for patients who have received at least one previous treatment. Oncology Read full story Post navigation Previous: UK MHRA authorises orforglipron private prescriptionNext: Roche bets up to $2.3B in Hanmi pact for next-gen weight loss drug Related Stories Regulatory FDA clears Takeda, Protagonist’s first-in-class PV drug pharminent August 31, 2026 Regulatory FDA green lights Priovant drug for rare skin disease pharminent August 28, 2026 Regulatory Neurocrine receives FDA IND Acceptance for Alzheimer’s Ph2 pharminent August 26, 2026
